LIXT — Lixte Biotechnology Holdings Balance Sheet
0.000.00%
Last trade - 00:00- $23.10m
- $20.31m
Annual balance sheet for Lixte Biotechnology Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 5.07 | 4.82 | 5.35 | 4.2 | 1.04 |
| Net Total Receivables | 0 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5.23 | 5.09 | 5.56 | 4.31 | 1.15 |
| Total Assets | 5.23 | 5.09 | 5.56 | 4.31 | 1.15 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.217 | 0.303 | 0.396 | 0.314 | 0.318 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.217 | 0.303 | 0.396 | 0.314 | 0.318 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 5.01 | 4.79 | 5.17 | 3.99 | 0.827 |
| Total Liabilities & Shareholders' Equity | 5.23 | 5.09 | 5.56 | 4.31 | 1.15 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |